Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Torri V, Liberati A
Eye Clinic, University of Milan, Italy.
Arch Ophthalmol. 1993 Jan;111(1):96-103. doi: 10.1001/archopht.1993.01090010100034.
A systematic quantitative and qualitative overview of published randomized clinical trials was undertaken to assess the yield of medical treatment on the outcome of patients with primary open angle glaucoma. Reports of 102 randomized clinical trials were published between 1975 and 1991, totalling about 5000 patients. Only 16% (16/102) of the trials were, however, properly designed (ie, comparing an active treatment with a placebo-treated or untreated control group) to answer the question of whether any medical treatment can effectively cure patients with primary open angle glaucoma. Pooled analysis showed a moderate yet statistically significant reduction in mean intraocular pressure (-4.9 mm Hg; 95% confidence interval [CI], -7.3 to -2.5 mm Hg); however, data on long-term visual field changes were available in only three randomized clinical trials, and their statistical combination failed to show a significant protective effect of active treatment (odds ratio, 0.75; 95% CI, 0.42 to 1.35). All of the remaining 86 randomized clinical trials looked at the effectiveness of one drug vs another in lowering intraocular pressure and were thus of no use in the overview. Practicing ophthalmologists should be aware that the effectiveness of pressure-lowering agents in the treatment of primary open angle glaucoma is still to be determined and that the vast majority of published trials are not appropriate to guide clinical practice. It is urgent to plan trials with end-point and follow-up duration that is fully relevant for the health of patients.
我们对已发表的随机临床试验进行了系统的定量和定性综述,以评估药物治疗对原发性开角型青光眼患者预后的效果。1975年至1991年间发表了102项随机临床试验报告,涉及约5000名患者。然而,只有16%(16/102)的试验设计合理(即将一种积极治疗方法与安慰剂治疗组或未治疗的对照组进行比较),以回答任何药物治疗是否能有效治愈原发性开角型青光眼患者的问题。汇总分析显示,平均眼压有适度但具有统计学意义的降低(-4.9 mmHg;95%置信区间[CI],-7.3至-2.5 mmHg);然而,只有三项随机临床试验提供了长期视野变化的数据,对这些数据进行统计合并后未能显示积极治疗有显著的保护作用(优势比,0.75;95%CI,0.42至1.35)。其余86项随机临床试验均着眼于一种药物与另一种药物降低眼压的有效性,因此对本综述毫无用处。执业眼科医生应意识到,降低眼压药物在治疗原发性开角型青光眼中的有效性仍有待确定,而且绝大多数已发表的试验并不适合指导临床实践。迫切需要规划具有与患者健康完全相关的终点和随访持续时间的试验。